Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal MelanomaLisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and PrednisoneDana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma CohortsSumanta K Pal, Yohann Loriot, Andrea Necchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Clinical Genitourinary Cancer|July 10, 2020
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 StudyJoshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, et al.
Pageof 9